title: [Efficacy and toxicity of transcatheter arterial chemoembolization with Cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma].
abstract: In this study we evaluated the efficacy and toxicity of transcatheter arterial chemoembolization (TACE) with Cisplatin (CDDP)-Lipiodol (LIP) suspension in 24 patients with advanced hepatocellular carcinoma (HCC). Eligibility criteria were as follows; unresectable HCC, age <75 years, performance status (PS) 0-2, Child-Pugh A or B and adequate heart and renal function. When TACE was performed, the catheter was placed selectively in feeding arteries of the tumors, and CDDP-LIP suspension (20 mg/mL) was injected followed by gelatin sponge particles. The direct and total effect on tumors were evaluated 3 and 6 months after TACE, respectively. As for a direct effect, complete and partial response rates were 54.2% and 25%, respectively. As for a total effect, complete and partial response rates were 41.7% and 4.1%, respectively. Grade 3/4 drug-related toxicities were as follows: thrombocytopenia (13%), appetite loss (8%) and nausea (4%). These severe side effects disappeared within 10 days after TACE. No renal and hepatic dysfunction was encountered, and no drug-related deaths occurred. TACE with CDDP suspended in LIP may provide some clinical benefits with relatively tolerable toxicities.
authors.affiliation: Dept. of Gastroenterological Surgery, Kyoto University Graduate School of Medicine.
authors.forename: Naoki
authors.initials: N
authors.lastname: Uyama
authors.forename: Etsuro
authors.initials: E
authors.lastname: Hatano
authors.forename: Yoji
authors.initials: Y
authors.lastname: Maetani
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Isoda
authors.forename: Toshiya
authors.initials: T
authors.lastname: Shibata
authors.forename: Kojiro
authors.initials: K
authors.lastname: Taura
authors.forename: Shoshiro
authors.initials: S
authors.lastname: Oe
authors.forename: Masato
authors.initials: M
authors.lastname: Naito
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yasuchika
authors.forename: Hideaki
authors.initials: H
authors.lastname: Fujii
authors.forename: Iwao
authors.initials: I
authors.lastname: Ikai
authors.forename: Shinji
authors.initials: S
authors.lastname: Uemoto
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000633:toxicity*; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013535:Suspensions
chemical_list: D000970:Antineoplastic Agents; D013535:Suspensions; D007459:Iodized Oil; D002945:Cisplatin